Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Early Phase 1
1(20.0%)
Phase 1
1(20.0%)
N/A
1(20.0%)
5Total
Phase 2(2)
Early Phase 1(1)
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06430671Phase 1Active Not Recruiting

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Role: collaborator

NCT05262218Phase 2Completed

Therapeutic Effect of PBF-680 in Patients With COPD

Role: collaborator

NCT03369262Phase 2Unknown

PoC Study of OBE022 in Threatened Preterm Labour

Role: collaborator

NCT04791007Early Phase 1Completed

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

Role: collaborator

NCT03058224Not ApplicableCompleted

Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia

Role: collaborator

All 5 trials loaded